Search Results 201-210 of 17294 for hba1c

  1. A Study Comparing the Safety and Effectiveness of Lonapegsomatropin with Placebo and Somatropin in Adults with Growth Hormone Deficiency - Mayo Clinic

    Poorly controlled diabetes, defined as HbA1c >7.5% at screening. 2. Diabetes mellitus (defined as HbA1c ≥6.5% and/or fasting plasma glucose ≥126 mg/dL ...

  2. https://www.mayoclinic.org/spanish_patient_consumer_recipe.xml

  3. Niacin Regulation of Regional Lipolysis - Clinical Trials

    * Previous labs: HbA1C \< 6.5% for non-diabetic UBO; Fasting glucose \< 126 mg/dl for non-diabetic UBO; Hb ≥ 11.0 for women and ≥ 12 for men; platelets ...

  4. https://www.mayoclinic.org/spanish_organization_concepts.xml

  5. Statins For The Treatment Of NASH - Mayo Clinic

    HbA1C > 9.0 %; 2. Neutrophil count < 1.0 x 10^9 / L; 3. Platelets < 100 10^9 / L; 4. Hemoglobin < 10 g/dl; 5. Albumin < 3.5 g; 6. Prolonged international ...

  6. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  7. Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) - Mayo Clinic

    HbA1C > % (75 mmol/mol), as assessed using NGSP certified method and standardized to DCCT assay. Fasting Plasma Glucose > 270 mg/dL (15 mmol/L). Fasting ...

  8. A Study to Evaluate the Safety and Effectiveness of Felzartamab in IgA Nephropathy - Mayo Clinic

    Participation eligibility · Glycated hemoglobin (HbA1c) < 8.0% or < 64 mmoL/mol.; · No diabetic retinopathy known; · No peripheral neuropathy known.

  9. Phase III Copanlisib In Rituximab-refractory INHL - Mayo Clinic

    Type I or II diabetes mellitus with HbA1c > 8.5% at Screening. Known history of human immunodeficiency virus (HIV) infection. Active clinically serious ...

  10. Small bowel endoluminal bariatric and metabolic therapies - Mayo Clinic

    " DMR appears to improve glycemic control independent of weight loss," explains Dr. Badurdeen. "Participants in a multicenter study had decreases in HbA1c and ...